Mrna-Based Vaccines Suppliers & Bulk Manufacturers
Available Forms: Injectable suspension
Available Strengths: 30 µg and 100 µg
Reference Brands: Comirnaty, Spikevax(US)
Category: Vaccines
mRNA vaccines work by delivering genetic instructions that enable cells to produce the coronavirus spike protein, triggering an immune response. They provide rapid, effective protection against COVID-19, reduce severe illness, support herd immunity, and are safe for most populations, supporting global vaccination efforts to control the pandemic. mRNA-based Vaccines is available in Injectable suspension and strengths such as 30 µg and 100 µg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, mRNA-based Vaccines is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
mRNA-based Vaccines can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
mRNA-based vaccines, such as Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax, are approved in both the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP and IVDR standards. In the US, FDA approval involves rigorous clinical trials, while in the EU, CE marking certifies conformity with in vitro diagnostic regulations. These vaccines undergo validation, stability testing, and quality audits, with comprehensive documentation including safety profiles, clinical trial data, and manufacturing processes. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring regulatory compliance guarantees safe, effective COVID-19 protection globally, supporting public health efforts.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
mRNA-based vaccines are used to prevent infectious diseases by stimulating the body’s immune system to produce a protective response against specific pathogens, such as viruses. The most well-known mRNA-based vaccines are those developed for COVID-19, which help the immune system recognize and fight the SARS-CoV-2 virus. These vaccines teach cells to produce a harmless piece of the virus (spike protein), triggering an immune response without using a live virus.
mRNA-based vaccines are made from messenger RNA (mRNA) that encodes the genetic instructions for cells to produce a viral protein. This mRNA is encapsulated within lipid nanoparticles that protect it and facilitate its delivery into human cells. Once inside the body, the mRNA instructs cells to make the target antigen, which then triggers an immune response.
Common trade names include Comirnaty (Pfizer-BioNTech COVID-19 Vaccine) and Spikevax (Moderna COVID-19 Vaccine).
The leading manufacturers of mRNA-based vaccines are Pfizer-BioNTech and Moderna. Other companies such as CureVac and Sanofi are also developing mRNA vaccine platforms for various infectious diseases and cancers.
There is no single generic name, as “mRNA-based vaccine” refers to a vaccine technology platform. For example, the generic name for Comirnaty is Tozinameran, and for Spikevax, it is Elasomeran.
Brand names include Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna).
mRNA-based vaccines are manufactured by Pfizer-BioNTech in the USA and Germany, and by Moderna in the USA and Switzerland. Additional production and fill-finish facilities are located in Belgium, Spain, and other parts of Europe to meet global demand.
Related Products
Respiratory Syncytial Virus Mrna Vaccine
Strength:
0.5 mL
Form: injection (prefilled syringe)
Reference Brands: mRESVIA (USA/EU)
View Details
Inactivated Vaccines
Strength:
Dose and concentration depend on formulations
Form: Injectable suspension (IM administration), Lyophilized powder for reconstitution
Reference Brands: Sinovac Coronavac. Covaxin(EU)
View Details
Viral Vector Vaccines
Strength:
0.5 mL
Form: Intramuscular injectable suspension (IM)
Reference Brands: US: Johnson & Johnson’s Janssen (Jcovden)
View Details
Meningococcal Vaccine
Strength:
0.5 mL
Form: Vial or pre-filled syringe (injectable), Conjugate vaccines
Reference Brands: Menactra, Menveo(US)
View DetailsQuick Response Guaranteed | Verified Suppliers
